Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO

ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
Eric Mou retweeted
Replying to @dgermain21
I used to be a vocal skeptic of Hans and a key GEP fan, some say as an OG for GEP. I used to lament Hans IHC as the only tool available for my patients, when many trials used GEP instead.
But I have been surprised by learning how IHC has dramatically improved over the last decade or so with availability of standardized antibody clones, use of auto strainers, and interpretation consistency.
How was I convinced?
We did a systematic meta-analysis of >2200 patients from 19 studies. We used the PRISMA diagnostic test accuracy framework for comparing Hans to GEP.
library.ehaweb.org/eha/2026/…
Remarkably, this analysis now clearly shows that Hans is consistently non-inferior to GEP across current modern studies at a 10% NI margin for Accuracy, Precision, and Specificity.
This solid performance of Hans IHC is very much in line with current CAP benchmarks for diagnostic tests, and within the margins of NanoString GEP using FFPE vs original frozen GEP as the original elusive gold standard.
Long live Hans as the best currently available SOC for COO across the globe.
Eric Mou retweeted
If you have not read this moving and courageous essay from Tatiana Schlossberg in the @NewYorker, please check it out. You may be wondering why inv(3) leukemia is so deadly? Here is a brief 🧵 (1/n)
Tatiana Schlossberg, the daughter of Caroline Kennedy, had just given birth when she was diagnosed with a rare form of leukemia. She writes about her fear of adding another tragedy to her family’s life. newyorkermag.visitlink.me/CL…
Eric Mou retweeted
Three years and tons of memories. I’m going to miss these guys. @UIowaCancer heme onc fellowship class of 2025!
Eric Mou retweeted
Peripheral T- and natural killer-cell lymphomas: ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up☆ - Annals of Oncology annalsofoncology.org/article…
Eric Mou retweeted
Grateful to have the opportunity to write this editorial on current management of classic Hodgkin lymphoma with Dr. Ranjana Advani dailynews.ascopubs.org/do/up…
Eric Mou retweeted
On behalf of @avajones_35 & her family, we thank all for your continued support as Ava takes on another battle & begins treatment for cancer. For those who have inquired, plz send cards to our @IowaWBB office. Your thoughts & prayers are also so appreciated. 🙏🏼God bless.
Eric Mou retweeted
Hawkeye fans and WBB fans let’s all do what we can to help Ava Jones!!
raygunsite.com/pages/search-…
Eric Mou retweeted
At his weekly presser today, Kirk Ferentz was asked how he formulates relationships with @UIchildrens Kid Captains & their families.
He gave a 3-minute answer, but this particular perspective right here is special.
Not many college football coaches have this in them. #Hawkeyes
Eric Mou retweeted
Feeling nostalgic this morning as Director Emeritus Dr. George Weiner proudly holds the official letter that first declared us a 'comprehensive' cancer center by @theNCI. As we approach 25 years, we reflect on the incredible strides the center has made!
Eric Mou retweeted
Monumental effort by GLOW team in publishing the largest analysis of NLPHL to date and answering many key questions about age specific risks, the prognostic impact of variant patterns, and developing a new LP-IPS: ascopubs.org/doi/10.1200/JCO… @glow_nlphl @JCO_ASCO @JamieFlerlage
Drove home from work today through gridlock traffic surrounding the arena, hours before tipoff. Just an unreal scene.
Eric Mou retweeted
excited to share work from my PhD in @jaehyukchoimd's lab, out today in @Nature. in collaboration with @KoleRoybal and @jcole_garcia, we leveraged mutations evolved in human T cells to empower anti-cancer T cells nature.com/articles/s41586-0…
Eric Mou retweeted
Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today @Nature. #lymsm 1/15
nature.com/articles/s41586-0… PDF link at bottom of this thread
Eric Mou retweeted
🙌 Great #HoLISTIC consortium meeting today (hodgkinconsortium.com)!
We look forward to presentations at @ASH_hematology (below) & the many ongoing & planned HL projects.
ash.confex.com/ash/2023/webp…
ash.confex.com/ash/2023/webp…
ash.confex.com/ash/2023/webp…
#ASH23 #dataanalytics #bigdata
Eric Mou retweeted
🙌Thrilled for the A-HIPI to be part of the upcoming Best of @JCO_ASCO Hematologic Malignancies Edition (paper here: ascopubs.org/doi/abs/10.1200…).
🙏A big TY to all global collaborators part of the HoLISTIC consortium (hodgkinconsortium.com/), now >18,000 cases.
Much more to come!
Eric Mou retweeted
As a T-cell lymphoma specialist, I can tell you this is exceedingly rare. In an email sent in response to this announcement to T-cell docs at ~ 20 of the largest centers, none of us have seen this. @lymphomaphilia @bpromd @jaehyukchoimd
Eric Mou retweeted
I'm on the inpatient oncology service this week @YaleCancer @SmilowCancer. I ♥️ this time of year with new @YaleMed interns! I'm feeling energized, inspired and a bit nostalgic about my own intern year (22 years ago!!).
@MarkDSiegel1
🧵1/

































